Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-5.7
Face value
--
Shares outstanding
5,695,490
CFO
$-34.61 Mln
EBITDA
$-75.97 Mln
Net Profit
$-120.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
180 Life Sciences (ATNF)
| -52.5 | -16.4 | -23.5 | -40.8 | -86.0 | -81.7 | -- |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
180 Life Sciences (ATNF)
| -54.9 | -93.7 | -95.7 | 42.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
180 Life Sciences (ATNF)
|
0.9 | 4.9 | 0.0 | -7.5 | -- | -130.6 | -- | 0.6 |
| 49.3 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.4 | 8,290.2 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 147.4 | 7,242.1 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.5 | 10,001.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 43.4 | 11,009.2 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.4 | 5.2 | |
| 52.8 | 6,507.3 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 308.6 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 25.7 | 10,016.6 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 125.8 | 12,524.1 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.9 | 4.9 |
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development... platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California. Address: Building 4, Palo Alto, CA, United States, 94306 Read more
Co-Founder & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder & Executive Chairman
Dr. Lawrence Steinman BA, M.D., Ph.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of 180 Life Sciences Corp (ATNF) stood at $ 16 Mln as on 31-Mar-25
The share price of 180 Life Sciences Corp (ATNF) is $0.87 (NASDAQ) as of 23-Jun-2025 16:00 EDT. 180 Life Sciences Corp (ATNF) has given a return of -86.05% in the last 3 years.
180 Life Sciences Corp (ATNF) has a market capitalisation of $ 5 Mln as on 23-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of 180 Life Sciences Corp (ATNF) is 0.64 times as on 23-Jun-2025, a 77% discount to its peers’ median range of 2.79 times.
Since, TTM earnings of 180 Life Sciences Corp (ATNF) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 180 Life Sciences Corp (ATNF) and enter the required number of quantities and click on buy to purchase the shares of 180 Life Sciences Corp (ATNF).
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California. Address: Building 4, Palo Alto, CA, United States, 94306
The CEO & director of Dr. Lawrence Steinman BA, M.D., Ph.D.. is 180 Life Sciences Corp (ATNF), and CFO & Sr. VP is Dr. Lawrence Steinman BA, M.D., Ph.D..
There is no promoter pledging in 180 Life Sciences Corp (ATNF).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| 180 Life Sciences Corp. (ATNF) | Ratios |
|---|---|
|
Return on equity(%)
|
-130.56
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of 180 Life Sciences Corp (ATNF) was $0 Mln.
$0.00
(
